



March 18, 2024  
Kidswell Bio Corporation  
Code: 4584 (Growth Market, TSE)  
Shinya Kurebayashi, President & CEO

## Announcement of the loan arrangement from Japan Finance Corporation

Kidswell Bio Corporation (KWB) resolved the loan arrangement from Japan Finance Corporation (JFC) to secure the manufacturing working capital to ensure stable supply of biosimilar products.

### 1. Purpose of the loan arrangement

As announced in the "Working Capital Financing for stable supply for GBS-007 (18th series of stock acquisition rights with exercise price adjustment clause)" dated July 10, 2023, KWB is conducting various financings to secure the manufacturing working capital to increase the production of GBS-007 (Ranibizumab BS), which is the main revenue generator in the biosimilar business. In addition, demand for GBS-010 (Pegfilgrastim BS), launched in November 2023, is also expected to increase, so KWB resolved to arrange this loan at this time to ensure a stable supply of key products requiring API manufacturing.

### 2. Outline of the loan

(1) Lender	Japan Finance Corporation (JFC)
(2) Amount	400 million yen
(3) Loan interest	Interest rate stipulated in the loan program of JFC
(4) Borrowing date	March 18, 2024
(5) Repayment due date	February 28, 2027
(6) Collateral status	Unsecured and unguaranteed

### 3. Outlook

The impact of this matter on KWB's business and financial position is expected to be minimal.